Barely Significant
← all phrases

narrowly missed statistical significance

73 sentences · 73 papers · 247 search hits before verification

In the literature

4.2.3 ARNI in HFpEF The PARAGON-HF trial evaluated Sacubitril/valsartan vs valsartan in 4822 patients with HFpEF, and found reduced rates of the composite primary outcome of total hospitalisations for HF and death from cardiovascular causes (rate ratio 0.87), albeit this narrowly missed statistical significance (95% CI 0.75–1.01; p = 0.06) [ 29 ].
Additionally, in patients with compensated cirrhosis (MELD 10–17), autologous monocyte-derived macrophages demonstrated a favorable safety profile and clinical promising trends, including a reduction in MELD scores at day 90, a lower incidence of liver-related SAEs, and favorable anti-inflammatory cytokine changes, though the primary endpoint narrowly missed statistical significance (ΔΔMELD –0.87, p = 0.06).
Notably, two of the HFHC solvents (Calypsolv and EcoSolv) showed IL-8 dose–response curves strongly resembling ethanol’s pattern ( r ≈ 0.93), although correlations narrowly missed statistical significance ( p = 0.066), indicating a highly similar, though not conclusively identical, inflammatory response.
Although the primary composite outcome of all-cause mortality and heart failure events narrowly missed statistical significance (HR, 0.71; 95% CI, 0.49–1.03; p = 0.066), ablation-based rhythm control led to marked improvements in left ventricular ejection fraction, NT-proBNP levels, exercise capacity, and quality of life metrics compared to rate control [ 213 ].
5 In terms of clinical outcomes, two moderately sized randomized trials published prior to HEART‐FID (Ferric Carboxymaltose in Heart Failure with Iron Deficiency) demonstrated a reduction in HF hospitalizations and cardiovascular deaths in both hospitalized and stable patients which narrowly missed statistical significance. 6 , 7 The HEART‐FID trial further substantiated these results; thus, consideration of iron replacement in eligible patients with HF and ID is warranted. 8 , 9 The efficacy and safety of intravenous ferric carboxymaltose (FCM) has previously been demonstrated in multiple disease states (e.g. chronic kidney disease [CKD], inflammatory bowel disease, heavy uterine bleeding, postpartum period) including HF. 7 , 10 , 11 Prior studies with FCM have shown transient, asymptomatic hypophosphataemia.